CLEARMIND MEDICINE INC.

Andere talen Clearmind Medicine Inc.

Aandelen

CMND

CA1850534027

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 28-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,14 ^USD	-0,87%		-5,00%	-59,43%

10/05	Clearmind Medicine Inc. boekt vooruitgang in zijn eigen op psychedelica gebaseerde synthetische alcoholhoudende drank	CI
07/05	Clearmind Medicine verwerft exclusieve wereldwijde rechten op baanbrekende psychedelische verbindingen voor de behandeling van PTSS	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	13/05
Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10/05
Clearmind Medicine Inc. Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product	10/05
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07/05
Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment	07/05
Clearmind Applies to Cease Being a Reporting Issuer in Canada	30/04
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders	17/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders	10/04
Clearmind Medicine CEO Issues Letter to Shareholders	09/04
Clearmind Medicine Inc. Announces International Patent Application for Preventing and Treating Depression	27/03
Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China	19/03
Clearmind Medicine Inc. Receives Divisional Patent Approval by the China National Intellectual Property Administration	19/03
Clearmind Medicine : Condensed Interim Consolidated Financial Statements - Form 6-K	19/03
Clearmind Medicine Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	18/03
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals	08-03-22
Clearmind Medicine : Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board	14-10-21
Clearmind Medicine : to Host ‘Psychedelics for Alcoholism‘ Virtual Educational Event on October 20	01-10-21

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

-40 % Aanbod van beperkte duur: onze abonnementen leiden je naar de beste beleggingen van morgen.

PROFITEER NU